SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Duramed (DRMD) Synthetic Estrogen Product -- Ignore unavailable to you. Want to Upgrade?

To: vestor who wrote (1834)7/15/2001 9:40:24 PM
From: Thure Meyer  Respond to of 1837
 
The expired patent information is good. I will get Business Week. I am not that interested in penny stocks right now though.

thure



To: vestor who wrote (1834)8/7/2001 6:55:16 AM
From: Thure Meyer  Read Replies (1) | Respond to of 1837
 
Vestor,

Record quarterly results for Duramed. And, this is what annoyed me about the Barr purchase. On their own it looks like Duramed could reach $0.25+ per/share per quarter. That would be $1.00+ in earnings each year and at a multiple of 40, this translates into a $40. plus stock.

I think they should have waited a couple of quarters before selling out and the terms would have been much better.

Thure


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News